Involved-field irradiation in combination with total-body irradiation (TBI) does not increase short-term toxicity compared to tbi alone in patients with advanced-stage low-grade non-Hodgkin lymphoma

Strahlentherapie und Onkologie

Volumn 178, Issue 5, 2002, Pages 245-251

  Ott, Marcel ^a   Schmidberger, Heinz ^a   Wörmann, Bernhard ^a   Albrecht, Clemens F ^a   Pradier, Olivier ^a   Hess, Clemens F ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

High dose chemotherapy; Involved field irradiation; Non Hodgkin lymphoma; Total body irradiation; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MITOXANTRONE; PREDNIMUSTINE; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MALE; MYALGIA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVARY FUNCTION; RADIATION DOSE; RADIATION FIELD; RADIATION INJURY; RADIATION PNEUMONIA; SEXUAL DYSFUNCTION; TESTIS FUNCTION; WHOLE BODY RADIATION;

ADULT; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHOMA, LOW-GRADE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; RADIATION INJURIES; RADIOTHERAPY DOSAGE; WHOLE-BODY IRRADIATION;

EID: 0036103850     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-002-0932-9     Document Type: Article

References (49)

1. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up
2. The influence of total dose, fractionation, dose rate, and distribution of total body irradiation on bone marrow transplantation
3. The incidence of interstitial pneumonitis; comparison of total body irradiation schedules for allogeneic bone marrow transplantation
4. Long-term follow-up after high-dose therapy for high-risk multiple myeloma
5. Mediastinal Hodgkin lymphomas in computerized tomography. Comparison of exact CT-assisted volumetry and volume assessment using simple geometric models
6. Regimen-related toxicity in patients undergoing bone marrow transplantation
7. Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: A study of the European Group for Blood and Marrow Transplantation
8. Veno-occlusive liver disease after tota infradiaphragmatic lymphoid irradiation. A rare complication
9. Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation
10. Immediate toxicity during fractionated total body irradiation as conditioning for bone marrow transplantation
11. Total-body irradiation in the treatment of lymphocytic lymphoma
12. Prospective study of the clinical symptoms of therapeutic whole body irradiation
13. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell trans-plantation for lymphoid malignancies
14. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone
15. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-pro-tocols: Results of the German cooperative study
16. Tolerance of normal tissue to therapeutic irradiation
17. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
18. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse
19. Total body irradiation and high-dose melphalan with bone marrow transplantation at Istituto Nazionale Tumori, Milan, Italy
20. High-dose sequential chemoradio-therapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma
21. Consequences of two different doses to the lungs during a single dose of total body irradiation: Results of a randomized study on 85 patients
22. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation
23. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma
24. Testicular function after cyto-toxic chemotherapy: Evidence of Leydig cell insufficiency
25. Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma
26. Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohe-matopoietic disorders
27. Endocrine function and bone metabolism 5 years after autologous bone marrow/blood-derived progeni-tor cell ransplantation
28. Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: Analysis of 300 cases in a single institution
29. Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease
30. Lung damage following bone marrow transplantation after hyperfractionated total body irradiation
31. Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation
32. LENT SOMA scales for all anatomic sites
33. Endocrine and reproductive dysfunction following fractionated total body irradiation in adults
34. Lethal pulmonary toxicity after autologous bone marrow transplantation/peripheral blood stem cell transplantation for hematological malignancies
35. High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: A single centre experience of 123 patients
36. Therapy-related myelodys-plasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies
37. Renal toxicity after allogeneic bone marrow transplantation: The combined effects of total-body irradiation and graft-versus-host disease
38. Total body irradiation; the lung as a critical organ
39. Total-body irradiation before bone marrow transplantation. Results of two randomized instantaneous dose rates in 157 patients
40. Neurobehavioral toxicity of total body irradiation: A follow-up in long-term survivors
41. Marrow transplantation following escalating doses of fractionated total body irradiation and cyclophosphamide - A phase I trial
42. Neuropsychological effects of cranial radiation: Current knowledge and future directions
43. Total body irradiation for marrow or stem-cell transplantation
44. Patterns of failure following total body irradiation and bone marrow transplantation with or without a radiotherapy boost for advanced neuroblastoma
45. Thyroid dysfunction among long-term survivors of bone marrow transplantation
46. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: Analysis of the MRC AML 10 trial
47. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma
48. Interstitial pneumonitis after total, body irradiation: Effect of partial lung shielding
49. Cataract incidence after total-body irradiation